Trastuzumab biosimilar (Biocon/Mylan)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTrastuzumab biosimilar (Biocon/Mylan)
Drug Alias NameTrastuzumab-dkst曲妥珠单抗生物仿制药 (Biocon/Mylan)曲妥珠单抗生物类似药 (Biocon/Mylan)HerMyl-1401O trastuzumabHercules +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsUterine Cervical Neoplasms +[7] 
Global Approved IndicationsStomach NeoplasmsEsophageal NeoplasmsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2013/01/01
Country/TerritoryCanadaUnited StatesUkraine +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiocon LtdMylan Nv
China Registration ClassN/A

Develop Information

Active CompaniesBiosimilar Collaborations Ireland LtdNational Cancer InstituteMylan Gmbh
Inactive CompaniesMylan Inc
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsUterine Cervical Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC03
Related LinksN/A